Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.